Indivior Appoints Patrick Barry as Chief Commercial Officer, Strengthening Leadership in Opioid Treatment

Indivior Strengthens Leadership with New CCO Appointment

Indivior PLC, a leading global pharmaceutical company, has announced the appointment of Patrick Barry as its new Chief Commercial Officer (CCO), effective June 2, 2025. This strategic move is set to enhance the company's efforts in treating opioid use disorder, with a particular focus on its flagship product, SUBLOCADE® (buprenorphine extended-release) Injection.

As the CCO, Barry will oversee Indivior's commercial growth strategies and operations. His role is crucial as the company aims to further its mission of transforming opioid use disorder treatment. Barry's extensive experience in the pharmaceutical sector makes him an asset to Indivior's executive team. According to Joe Ciaffoni, Indivior's CEO, Barry is a well-respected leader with a proven track record in driving growth through branded medicines. His experience will be pivotal in unlocking Indivior's full potential.

With over 30 years in the industry, Barry's resume includes a solid history of building effective commercial teams that deliver sustained revenue growth across various product lines. Before joining Indivior, he served as executive vice president and CCO for Endo Pharmaceuticals, where he managed all commercial activities across the U.S. business segments and was accountable for revenues nearing $2 billion.

Barry expressed enthusiasm about his new role, stating, "I am honored to join Indivior at such a pivotal time for the company. Indivior has built a strong foundation and is well-positioned to broaden its leadership in the opioid use disorder space." He is eager to collaborate with the team to grow SUBLOCADE and maximize the potential of Indivior's product portfolio.

Prior to his tenure at Endo, Barry spent over 20 years at Sanofi, where he held various senior leadership positions. His experience spans across specialties, including pharmaceuticals and medical aesthetics, and he has a history of successfully leading turnaround scenarios, launching products, and driving market development.

In addition to his industry expertise, Barry holds an MBA from Cornell University and a bachelor's degree in public relations and marketing from McKendree University. His strong educational background complements his practical experience, making him a fitting leader for Indivior's ambitious plans.

About Indivior PLC

Indivior is dedicated to revolutionizing the treatment landscape for opioid use disorder, aiming to provide all patients globally with access to effective, evidence-based treatments. With its headquarter located in Richmond, Virginia, Indivior's portfolio is accessible in over 30 countries worldwide and employs more than 1,000 individuals globally. The company prioritizes expanding its pipeline of product candidates alongside its commitment to providing effective OUD treatments, contributing to a solution for what has become a significant global health crisis.

For more information about Indivior and its initiatives, visit www.indivior.com and connect with them on LinkedIn.